Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.56 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.55 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.42 |
| ▸ | FYN | P06241 | 7/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18366702 | 0.82 | MAP3K5 (0.55) | EGLN2MAP3K5NUDT1FYNJAK1 | |
| SCHEMBL2772772 | 0.82 | NUDT1 (0.65) | EGLN2MAP3K5NUDT1FYNJAK1 | |
| SCHEMBL19659204 | 0.79 | EGLN2 (0.68) | EGLN2NUDT1JAK1JAK2JAK3 | |
| SCHEMBL19658961 | 0.77 | MAP3K5 (0.57) | EGLN2MAP3K5NUDT1FYNJAK1 | |
| SCHEMBL2145340 | 0.75 | MAP3K5 (0.67) | MAP3K5JAK1JAK2JAK3PTK2 | |
| Cyclopropane SCHEMBL16986945 | 0.75 | MAP3K5 (0.73) | EGLN2MAP3K5JAK1JAK2JAK3 | |
| SCHEMBL16248930 | 0.75 | EGLN2 (0.67) | EGLN2NUDT1FYNJAK1JAK2 | |
| SCHEMBL16248944 | 0.74 | EGLN2 (0.57) | EGLN2NUDT1JAK1JAK2 | |
| SCHEMBL2788079 | 0.72 | MAP3K5 (0.85) | EGLN2MAP3K5JAK1JAK2 | |
| SCHEMBL2787249 | 0.72 | MAP3K5 (0.61) | EGLN2MAP3K5JAK1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3760625-A1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | F. Hoffmann-La Roche AG (CH) | 2021-01-06 | — | — | EP | disclosed |
| WO-2017004500-A9 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |